Connection

MANDEEP BAJAJ to Blood Glucose

This is a "connection" page, showing publications MANDEEP BAJAJ has written about Blood Glucose.
Connection Strength

2.045
  1. DPP-4 inhibitors and atherosclerosis: the promise. Atherosclerosis. 2013 Apr; 227(2):224-5.
    View in: PubMed
    Score: 0.308
  2. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous souffl?. Metab Syndr Relat Disord. 2009 Apr; 7(2):79-81.
    View in: PubMed
    Score: 0.237
  3. Effect of point-of-care on maintenance of glycemic control as measured by A1C. Diabetes Care. 2007 Mar; 30(3):713-5.
    View in: PubMed
    Score: 0.205
  4. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003 Jun; 52(6):1364-70.
    View in: PubMed
    Score: 0.158
  5. Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes. 2002 Oct; 51(10):3043-8.
    View in: PubMed
    Score: 0.151
  6. Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans. Am J Physiol Endocrinol Metab. 2002 Aug; 283(2):E346-52.
    View in: PubMed
    Score: 0.149
  7. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014 Oct; 28(5):447-57.
    View in: PubMed
    Score: 0.087
  8. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med. 2014 Dec; 31(12):1505-14.
    View in: PubMed
    Score: 0.085
  9. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis. 2012 Jul; 223(1):204-8.
    View in: PubMed
    Score: 0.073
  10. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011 Dec; 19(12):2310-5.
    View in: PubMed
    Score: 0.069
  11. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 2007 Aug; 50(8):1723-31.
    View in: PubMed
    Score: 0.052
  12. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother. 2006 Jun; 7(8):1055-64.
    View in: PubMed
    Score: 0.049
  13. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord. 2004 Jun; 28(6):783-9.
    View in: PubMed
    Score: 0.042
  14. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Jan; 89(1):200-6.
    View in: PubMed
    Score: 0.041
  15. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol. 2003 May-Jun; 10(3):311-23.
    View in: PubMed
    Score: 0.039
  16. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2002 Jun; 282(6):E1360-8.
    View in: PubMed
    Score: 0.037
  17. SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Cardiovasc Drugs Ther. 2022 12; 36(6):1091-1108.
    View in: PubMed
    Score: 0.035
  18. miR-30a targets gene networks that promote browning of human and mouse adipocytes. Am J Physiol Endocrinol Metab. 2020 10 01; 319(4):E667-E677.
    View in: PubMed
    Score: 0.033
  19. Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. Cardiovasc Drugs Ther. 2020 12; 34(6):835-848.
    View in: PubMed
    Score: 0.033
  20. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care. 1999 Jul; 22(7):1022-8.
    View in: PubMed
    Score: 0.030
  21. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care. 1998 Aug; 21(8):1330-8.
    View in: PubMed
    Score: 0.028
  22. Dickkopf-1 (DKK1) phosphatase and tensin homolog on chromosome 10 (PTEN) crosstalk via microRNA interference in the diabetic heart. Basic Res Cardiol. 2013 May; 108(3):352.
    View in: PubMed
    Score: 0.020
  23. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
    View in: PubMed
    Score: 0.019
  24. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
    View in: PubMed
    Score: 0.019
  25. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab. 2007 Jun; 292(6):E1775-81.
    View in: PubMed
    Score: 0.013
  26. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab. 2005 Feb; 90(2):1100-5.
    View in: PubMed
    Score: 0.011
  27. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004 Sep; 287(3):E537-46.
    View in: PubMed
    Score: 0.011
  28. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003 Oct; 52(10):2461-74.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.